Loading
Life sciences · Journal article
Antibodies · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: A leading cause of cancer-related mortality worldwide, gastrointestinal (GI) cancers are often recalcitrant to single agent therapies. Dysregulations of the EGFR, cMET, and VEGF pathways are frequently observed together in these malignancies, making simultaneous multi-targeted therapy a promising strategy. Objectives: TAVO412, a trispecific antibody against EGFR, cMET, and VEGFA, employed complementary mechanisms of action to inhibit multiple GI cancer cell lines. Methods/Results: TAVO412 effectively suppressed phosphorylation of the targeted receptors, thereby inhibiting cancer cell proliferation in vitro. The antibody, engineered with enhanced Fc function, displayed strong antibody-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. In vivo studies demonstrated that the anti-VEGFA domain design was central to drug efficacy, with the non-cleavable linker format performing optimally, presumably due to tumor-localized VEGF binding. In a pancreatic cancer model, antitumor activity was primarily driven by anti-VEGF and anti-EGFR activities. Moreover, TAVO412 demonstrated superior antitumor activity compared to bevacizumab or amivantamab monotherapy, and was as effective as their combination in colorectal and esophageal cancer models. Conclusions: Collectively, these preclinical findings laid the groundwork for clinical trials of TAVO412 in patients with advanced gastrointestinal cancers expressing EGFR, cMET, and VEGF.